Ultragenyx Pharmaceutical Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of RARE for the last quarter is 139.49 M USD, and it's 5.12% lower compared to the previous quarter. The net income of Q3 24 is -133.52 M USD.